3 news items
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
CGTX
7 May 24
to fund operations and capital expenditures through the second quarter of 2025. Research and development expenses were $10.6 million
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
CGTX
26 Mar 24
, the Company estimates that it has sufficient cash to fund operations and capital expenditures through May of 2025. Research
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
CGTX
11 Mar 24
to fund research, clinical development, process development and manufacturing of Cognition's product candidates, working capital, capital expenditures
- Prev
- 1
- Next